A biotechnology firm has engineered a new monoclonal antibody, 'Inflam-X', designed to reduce joint inflammation in patients with rheumatoid arthritis.
Devise a clinical trial plan that researchers could use to test the effectiveness of this new monoclonal antibody treatment using 80 adult volunteers who suffer from active joint inflammation.
